Syros Pharmaceuticals Inc (NAS:SYRS)
$ 1.5675 -0.035 (-2.18%) Market Cap: 42.02 Mil Enterprise Value: 24.59 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 38/100

Q4 2019 Syros Pharmaceuticals Inc Earnings Call Transcript

Mar 05, 2020 / 01:30PM GMT
Release Date Price: $60.2 (-3.68%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Fourth Quarter 2019 Syros Pharmaceuticals, Inc., Earnings Conference Call. (Operator Instructions) It is now my pleasure to introduce Vice President of Corporate Communications and Investor Relations, Naomi Aoki.

Naomi Aoki
Syros Pharmaceuticals, Inc. - VP of Corporate Communications & IR

Thank you. This morning, we issued a press release with our fourth quarter and full year 2019 financial results along with anticipated future milestones and recent accomplishments. This release is available on the Investors and Media section of Syros' website at www.syros.com.

We will begin the call with prepared remarks by Dr. Nancy Simonian, our Chief Executive Officer; and Joe Ferra, our Chief Financial Officer. We'll then open the call for question. Dr. David Roth, our Chief Medical Officer; Dr. Eric Olson, our Chief Scientific Officer; and Dr. Jeremy Springhorn, our Chief Business Officer, are also on the call and will be

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot